NCT00004747已完成2 期
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis
National Center for Research Resources (NCRR)0 个研究点目标入组 170 人开始时间: 1995年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 170
研究概览
简要总结
OBJECTIVES: I. Assess the efficacy of monthly intravenous mucoid exopolysaccharide Pseudomonas aeruginosa immune globulin (MEP IGIV) given over 1 year in reducing the frequency of acute pulmonary exacerbation in patients with cystic fibrosis, mild to moderate pulmonary disease, and mucoid P. aeruginosa colonization.
II. Assess the effect of MEP IGIV on FEV1, sputum density of mucoid P. aeruginosa, and the quality of life in these patients.
III. Assess the safety of monthly MEP IGIV. IV. Assess population-based MEP IGIV pharmacokinetics during chronic therapy.
详细描述
PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution.
Patients are randomly assigned to 1 of 3 groups: low-dose intravenous mucoid exopolysaccharide Pseudomonas aeruginosa immune globulin (MEP IVIG), high-dose MEP IVIG, or placebo. Therapy is administered every 28 days for 12 months. Treatment is not initiated in the presence of an acute asthmatic attack.
Concurrent chronic suppressive antibiotics are permitted.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •Disease Characteristics
- •Cystic fibrosis (CF) documented by pilocarpine iontophoresis sweat chloride greater than 60 mEq/L FEV1 30%-80% of predicted and within 20% of maximum values obtained in 12 months prior to entry Able to expectorate at least 1 g of sputum within 3 hours at screening
- •Mucoid Pseudomonas aeruginosa colonization documented in at least 2 serial expectorated sputum cultures in the year prior to entry Screening specimen meets requirement for 1 culture
- •Documented exacerbation of respiratory tract infection At least 1 hospitalization and/or course of parenteral or nebulized antibiotic therapy in each of the 2 years prior to entry
- •At least 2 serial spirometry tests over at least 6 months prior to entry FEV1 range no more than 15% relative to maximum value
- •None of the following within 6 months prior to entry: Pseudomonas (Burholderia) cepacia or atypical mycobacteria in respiratory tract Pulmonary hemorrhage with greater than 5% drop in hematocrit Pneumothorax requiring chest tube
- •No life-threatening CF sequelae, e.g.: Severe cirrhosis with ascites or bleeding Severe distal intestinal obstruction syndrome requiring cessation of oral intake Poorly controlled insulin-dependent diabetes with acetonuria
- •Prior/Concurrent Therapy
- •No concurrent participation in other investigational protocols
- •No prior investigational P. aeruginosa vaccine
- •At least 45 days since immune globulin or antibacterial monoclonal antibody
- •At least 4 weeks since investigational drugs
- •At least 2 weeks since systemic glucocorticoids
- •No requirement for systemic steroids during first 2 weeks of study
- •Patient Characteristics
- •Renal: Creatinine less than 2 mg/dL (1.5 mg/dL in patients under 50 kg)
- •No proteinuria
- •No hematuria
- •Cardiovascular: No cor pulmonale or other heart disease requiring chronic diuretics, afterload reduction, or cardiac glycoside therapy (e.g., digoxin)
- •Immunologic: Endogenous immunoreactive IgA at least 5 mg/dL
- •No hypersensitivity to immune globulin or human albumin
- •No primary or acquired immunodeficiency disease
- •Other: No clinical test abnormal on repeat and inconsistent with CF
- •No smoking 1 month prior to and during study
- •No suspected drug or alcohol abuse within 1 year prior to entry
- •No severe illness that precludes protocol participation
- •No disability, condition, or geographical location that would impair compliance
- •No psychiatric disorder, intellectual deficiency, or other condition that would limit informed consent
- •Negative pregnancy test required of fertile women
- •Medically acceptable contraception required of fertile women
- •Participating investigators, sub-investigators, study coordinators, and employees of participating investigators or immediate family members of any of these groups ineligible
- •Blood/body fluid analyses and other exams within 28 days prior to registration
排除标准
- 未提供
研究者
相似试验
已完成
2 期
A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese SubjectsHypercholesterolemia and High Risk for Cardiovascular EventsNCT01652703Amgen310
Unknown
1 期
A Pilot Study of FFP104 in Subjects With Crohn's DiseaseCrohn's DiseaseNCT02465944Fast Forward Pharmaceuticals24
已完成
2 期
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder StudyHypercholesterolemia, FamilialNCT01375751Amgen168
已完成
3 期
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed DyslipidemiaDiabetes, Hyperlipidemia, Mixed DyslipidemiaNCT02662569Amgen986
已完成
3 期
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular RiskHyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular EventsNCT01953328Amgen409